Literature DB >> 7380168

Studies on circulating immune complexes of the liver diseases. 5. Anti-DNA antibodies and C1q binding activity.

T Arima, J Narumoto, H Shimomura, T Yasuhara, K Kunishi, K Suwaki, H Nagashima.   

Abstract

Anti-dsDNA and anti-ssDNA antibodies, rheumatoid factors, HBsAg and C1q binding activity were determined in sera of patients with various liver diseases. Anti-dsDNA were only slightly increased in chronic aggressive hepatitis, activity severe and liver cirrhosis. A moderate elevation of anti-dsDNA was detected in possible lupoid hepatitis and it was highly increased in lupoid hepatitis as well as systemic lupus erythematosus. Non-specific elevation of anti-ssDNA titers were observed in all of the liver disease groups. In patients with increased anti-dsDNA titers, C1q binding activity and titers for rheumatoid factor and HBsAg tended to increase. According to reactivity of their sera to DNA, patients with liver disease could be divided in 4 groups: 1. high responders to dsDNA (lupoid hepatitis), 2. moderate responders to dsDNA (possible lupoid hepatitis or lupoid-like liver disease), 3. low responders (only positive for ssDNA), and 4. non-responders.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7380168     DOI: 10.1007/bf02774932

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  30 in total

1.  Evaluation of the simultaneous estimation of anti-dsDNA and anti-ssDNA antibodies for clinical purposes.

Authors:  A Lange
Journal:  Clin Exp Immunol       Date:  1978-03       Impact factor: 4.330

2.  Serum DNA binding activity in healthy subjects and in rheumatic disease.

Authors:  P Hasselbacher; E C LeRoy
Journal:  Arthritis Rheum       Date:  1974 Jan-Feb

3.  Immunologic factors and clinical activity in systemic lupus erythematosus.

Authors:  P H Schur; J Sandson
Journal:  N Engl J Med       Date:  1968-03-07       Impact factor: 91.245

4.  Immune complexes in acute and chronic liver disease.

Authors:  H C Thomas; D De Villiers; B Potter; H Hodgson; S Jain; D P Jewell; S Sherlock
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

5.  Anti-DNA activity in systemic lupus erythematosus. A diagnostic and therapeutic guide.

Authors:  G R Hughes; S A Cohen; C L Christian
Journal:  Ann Rheum Dis       Date:  1971-05       Impact factor: 19.103

6.  C1g precipitins in the sera of patients with systemic lupus erythematosus and other hypocomplementemic states: characterization of high and low molecular weight types.

Authors:  V Agnello; D Koffler; J W Eisenberg; R J Winchester; H G Kundel
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

7.  Detection of immune complexes in unheated sera by modified 125I-Clq binding test. Effect of heating on the binding of Clq by immune complexes and application of the test to systemic lupus erythematosus.

Authors:  R H Zubler; G Lange; P H Lambert; P A Miescher
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

8.  Studies on circulating immune complexes of the liver disease. 3. Conditions for Clq binding assay and low molecular weight Clq reactants.

Authors:  T Arima; J Narumoto; H Shimomura; K Suwaki; K Kunishi; T Yasuhara; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1980

9.  Studies of urticaria and acute serum sickness with the C1q precipitin test.

Authors:  P Lieberman; M C Rice; J E Mallette
Journal:  Arch Intern Med       Date:  1977-04

10.  Antibodies to polynucleotides in human sera: antigenic specificity and relation to disease.

Authors:  D Koffler; R Carr; V Agnello; R Thoburn; H G Kunkel
Journal:  J Exp Med       Date:  1971-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.